Diagnostic metabolomic blood tests for endoluminal gastrointestinal cancer - A systematic review and assessment of quality

Cancer Epidemiology Biomarkers and Prevention

Volumn 25, Issue 1, 2016, Pages 6-15

  Antonowicz, Stefan ^a   Kumar, Sacheen ^a   Wiggins, Tom ^a   Markar, Sheraz R ^a   Hanna, George B ^a  

^a IMPERIAL COLLEGE LONDON   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

BIOLOGICAL MARKER;

ANIMAL; BLOOD; BLOOD EXAMINATION; DISEASE COURSE; GASTROINTESTINAL NEOPLASMS; HUMAN; METABOLISM; METABOLOMICS; PROCEDURES; PROGNOSIS;

ANIMALS; BIOMARKERS; DISEASE PROGRESSION; GASTROINTESTINAL NEOPLASMS; HEMATOLOGIC TESTS; HUMANS; METABOLOMICS; PROGNOSIS;

EID: 84955326982     PISSN: 10559965     EISSN: None     Source Type: Journal    
DOI: 10.1158/1055-9965.EPI-15-0524     Document Type: Short Survey

References (77)

1. Foster MA, Attwood SE. Current guidelines fail young patients with oesophagogastric cancer. Gut 2002;51:296-7.
2. Vakil N, Moayyedi P, Fennerty MB, Talley NJ. Limited value of alarm features in the diagnosis of upper gastrointestinal malignancy: systematic review and meta-analysis. Gastroenterology 2006;131:390-401; quiz 659-60.
3. Steele CB, Rim SH, Joseph DA, King JB, Seeff LC; Centers for Disease, Control Prevention. Colorectal cancer incidence and screening - United States, 2008 and 2010. MMWR Surveill Summ 2013;62 Suppl 3:53-60.
4. Holme O, Loberg M, Kalager M, Bretthauer M, Hernan MA, Aas E, et al. Effect of flexible sigmoidoscopy screening on colorectal cancer incidence and mortality: a randomized clinical trial. JAMA 2014;312:606-15.
5. Schoen RE, Pinsky PF, Weissfeld JL, Yokochi LA, Church T, Laiyemo AO, et al. Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med 2012;366:2345-57.
6. Kumar S, Huang J, Abbassi-Ghadi N, Mackenzie HA, Veselkov KA, Hoare JM, et al. Mass spectrometric analysis of exhaled breath for the identification of volatile organic compound biomarkers in esophageal and gastric adenocarcinoma. Ann Surg 2015;262:981-90.
7. Imperiale TF, Ransohoff DF, Itzkowitz SH. Multitarget stool DNA testing for colorectal-cancer screening. N Engl J Med 2014;371:187-8.
8. Brett AS. Flexible sigmoidoscopy for colorectal cancer screening: more evidence, persistent ironies. JAMA 2014;312:601-2.
9. Nicholson JK, Lindon JC, Holmes E. 'Metabonomics': understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica 1999;29:1181-9.
10. Mamas M, Dunn WB, Neyses L, Goodacre R. The role of metabolites and metabolomics in clinically applicable biomarkers of disease. Arch Toxicol 2011;85:5-17.
11. Peng G, Hakim M, Broza YY, Billan S, Abdah-Bortnyak R, Kuten A, et al. Detection of lung, breast, colorectal, and prostate cancers from exhaled breath using a single array of nanosensors. Br J Cancer 2010;103:542-51.
12. Shvartsburg AA, Smith RD, Wilks A, Koehl A, Ruiz-Alonso D, Boyle B. Ultrafast differential ion mobility spectrometry at extreme electric fields in multichannel microchips. Anal Chem 2009;81:6489-95.
13. Xu Zq, Broza YY, Ionsecu R, Tisch U, Ding L, Liu H, et al. A nanomaterialbased breath test for distinguishing gastric cancer from benign gastric conditions. Br J Cancer 2013;108:941-50.
14. Monteiro MS, Carvalho M, Bastos ML, Guedes de Pinho P. Metabolomics analysis for biomarker discovery: advances and challenges. Curr Med Chem 2013;20:257-71.
15. Nicholson JK, Holmes E, Kinross JM, Darzi AW, Takats Z, Lindon JC. Metabolic phenotyping in clinical and surgical environments. Nature 2012;491:384-92.
16. Abbassi-Ghadi N, Kumar S, Huang J, Goldin R, Takats Z, Hanna GB. Metabolomic profiling of oesophago-gastric cancer: a systematic review. Eur J Cancer 2013;49:3625-37.
17. Liesenfeld DB, Habermann N, Owen RW, Scalbert A, Ulrich CM. Review of mass spectrometry-based metabolomics in cancer research. Cancer Epidemiol Biomarkers Prev 2013;22:2182-201.
18. Yakoub D, Keun HC, Goldin R, Hanna GB. Metabolic profiling detects field effects in nondysplastic tissue from esophageal cancer patients. Cancer Res 2010;70:9129-36.
19. Beckonert O, Coen M, Keun HC, Wang Y, Ebbels TM, Holmes E, et al. High-resolution magic-angle-spinning NMR spectroscopy for metabolic profiling of intact tissues. Nat Protoc 2010;5:1019-32.
20. Pepe MS, Etzioni R, Feng Z, Potter JD, Thompson ML, Thornquist M, et al. Phases of biomarker development for early detection of cancer. J Natl Cancer Inst 2001;93:1054-61.
21. Markar SR, Wiggins T, Kumar S, Hanna GB. Exhaled breath analysis for the diagnosis and assessment of endoluminal gastrointestinal diseases. J Clin Gastroenterol 2015;49:1-8.
22. Xia J, Broadhurst DI, Wilson M, Wishart DS. Translational biomarker discovery in clinical metabolomics: an introductory tutorial. Metabolomics 2013;9:280-99.
23. Beckonert O, Keun HC, Ebbels TM, Bundy J, Holmes E, Lindon JC, et al. Metabolic profiling, metabolomic and metabonomic procedures for NMR spectroscopy of urine, plasma, serum and tissue extracts. Nat Protoc 2007;2:2692-703.
24. Dunn WB, Broadhurst D, Begley P, Zelena E, Francis-McIntyre S, Anderson N, et al. Procedures for large-scale metabolic profiling of serum and plasma using gas chromatography and liquid chromatography coupled to mass spectrometry. Nat Protoc 2011;6:1060-83.
25. Lindon JC, Nicholson JK, Holmes E, Keun HC, Craig A, Pearce JT, et al. Summary recommendations for standardization and reporting of metabolic analyses. Nat Biotechnol 2005;23:833-8.
26. Members MSIB, Sansone SA, Fan T, Goodacre R, Griffin JL, Hardy NW, et al. The metabolomics standards initiative. Nat Biotechnol 2007;25:846-8.
27. Hundt S, Haug U, Brenner H. Blood markers for early detection of colorectal cancer: a systematic review. Cancer Epidemiol Biomarkers Prev 2007;16:1935-53.
28. Tao S, Hundt S, Haug U, Brenner H. Sensitivity estimates of blood-based tests for colorectal cancer detection: impact of overrepresentation of advanced stage disease. Am J Gastroenterol 2011;106:242-53.
29. Ritchie SA, Ahiahonu PW, Jayasinghe D, Heath D, Liu J, Lu Y, et al. Reduced levels of hydroxylated, polyunsaturated ultra long-chain fatty acids in the serum of colorectal cancer patients: implications for early screening and detection. BMC Med 2010;8:13.
30. Ritchie SA, Tonita J, Alvi R, Lehotay D, Elshoni H, Myat S, et al. Low-serum GTA-446 anti-inflammatory fatty acid levels as a new risk factor for colon cancer. Int J Cancer 2013;132:355-62.
31. Chadeau-Hyam M, Athersuch TJ, Keun HC, De Iorio M, Ebbels TMD, Jenab M, et al. Meeting-in-the-middle using metabolic profiling-a strategy for the identification of intermediate biomarkers in cohort studies. Biomarkers 2011;16:83-8.
32. Cross AJ, Moore SC, Boca S, Huang WY, Xiong X, Stolzenberg-Solomon R, et al. A prospective study of serum metabolites and colorectal cancer risk. Cancer 2014;120:3049-57.
33. Ma Y, Liu W, Peng J, Huang L, Zhang P, Zhao X, et al. A pilot study of gas chromatograph/mass spectrometry-based serum metabolic profiling of colorectal cancer after operation. Mol Biol Rep 2010;37:1403-11.
34. Ma H, Sorokin A, Mazein A, Selkov A, Selkov E, Demin O, et al. The Edinburgh Human Metabolic Network reconstruction and its functional analysis. Mol Syst Biol 2007;3:135.
35. Kanehisa M, Goto S, Sato Y, Furumichi M, Tanabe M. KEGG for integration and interpretation of large-scale molecular data sets. Nucleic Acids Res 2012;40:D109-14.
36. Gao J, Tarcea VG, Karnovsky A, Mirel BR, Weymouth TE, Beecher CW, et al. Metscape: a Cytoscape plug-in for visualizing and interpreting metabolomic data in the context of human metabolic networks. Bioinformatics 2010;26:971-3.
37. Bossuyt PM, Reitsma JB, Bruns DE, Gatsonis CA, Glasziou PP, Irwig LM, et al. Towards complete and, accurate reporting of studies of diagnostic accuracy: the STARD initiative. Brit Med J 2003;326:41-4.
38. Whiting PF, Rutjes AW, Westwood ME, Mallett S, Deeks JJ, Reitsma JB, et al. QUADAS-2: a revised tool for the quality assessment of diagnostic accuracy studies. Ann Intern Med 2011;155:529-36.
39. Djukovic D, Baniasadi HR, Kc R, Hammoud Z, Raftery D. Targeted serum metabolite profiling of nucleosides in esophageal adenocarcinoma. Rapid Commun Mass Spectrom 2010;24:3057-62.
40. Zhang J, Liu L, Wei S, Nagana Gowda GA, Hammoud Z, Kesler KA, et al. Metabolomics study of esophageal adenocarcinoma. J Thorac Cardiovasc Surg 2011;141:469-75, 75 e1-4.
41. Zhang J, Bowers J, Liu L, Wei S, Gowda GA, Hammoud Z, et al. Esophageal cancer metabolite biomarkers detected by LC-MS and NMR methods. PLoS One 2012;7:e30181.
42. Zhang X, Xu L, Shen J, Cao B, Cheng T, Zhao T, et al. Metabolic signatures of esophageal cancer: NMR-based metabolomics and UHPLC-based focused metabolomics of blood serum. Biochim Biophys Acta 2013;1832:1207-16.
43. Hasim A, Ma H, Mamtimin B, Abudula A, Niyaz M, Zhang LW, et al. Revealing the metabonomic variation of EC using (1)H-NMR spectroscopy and its association with the clinicopathological characteristics. Mol Biol Rep 2012;39:8955-64.
44. Liu R, Peng Y, Li X, Wang Y, Pan E, Guo W, et al. Identification of plasma metabolomic profiling for diagnosis of esophageal squamous-cell carcinoma using an UPLC/TOF/MS platform. Int J Mol Sci 2013;14:8899-911.
45. Xu J, Chen Y, Zhang R, Song Y, Cao J, Bi N, et al. Global and targeted metabolomics of esophageal squamous cell carcinoma discovers potential diagnostic and therapeutic biomarkers. Mol Cell Proteomics 2013;12:1306-18.
46. Jin H, Qiao F, Chen L, Lu C, Xu L, Gao X. Serum metabolomic signatures of lymph node metastasis of esophageal squamous cell carcinoma. J Proteome Res 2014;13:4091-103.
47. Ma H, Hasim A, Mamtimin B, Kong B, Zhang HP, Sheyhidin I. Plasma free amino acid profiling of esophageal cancer using high-performance liquid chromatography spectroscopy. World J Gastroenterol 2014;20:8653-9.
48. Yu L, Aa J, Xu J, Sun M, Qian S, Cheng L, et al. Metabolomic phenotype of gastric cancer and precancerous stages based on gas chromatography time-of-flight mass spectrometry. J Gastroenterol Hepatol 2011;26:1290-7.
49. Aa JY, Yu LZ, Sun M, Liu LS, Li MJ, Cao B, et al. Metabolic features of the tumor microenvironment of gastric cancer and the link to the systemic macroenvironment. Metabolomics 2012;8:164-73.
50. Song H, Peng J-S, Yao D-S, Yang Z-L, Liu H-L, Zeng Y-K, et al. Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. Braz J Med Biol Res 2012;45:78-85.
51. Zhao Z, Xiao Y, Elson P, Tan H, Plummer SJ, Berk M, et al. Plasma lysophosphatidylcholine levels: potential biomarkers for colorectal cancer. J Clin Oncol 2007;25:2696-701.
52. Qiu Y, Cai G, Su M, Chen T, Zheng X, Xu Y, et al. Serum metabolite profiling of human colorectal cancer using GC-TOFMS and UPLC-QTOFMS. J Proteome Res 2009;8:4844-50.
53. Ludwig C, Ward DG, Martin A, Viant MR, Ismail T, Johnson PJ, et al. Fast targeted multidimensional NMR metabolomics of colorectal cancer. Magn Reson Chem 2009;47 Suppl 1:S68-73.
54. Kondo Y, Nishiumi S, Shinohara M, Hatano N, Ikeda A, Yoshie T, et al. Serum fatty acid profiling of colorectal cancer by gas chromatography/mass spectrometry. Biomarkers Med 2011;5:451-60.
55. Leichtle AB, Nuoffer JM, Ceglarek U, Kase J, Conrad T, Witzigmann H, et al. Serum amino acid profiles and their alterations in colorectal cancer. Metabolomics 2012;8:643-53.
56. Ma Y, Zhang P, Wang F, Liu W, Yang J, Qin H. An integrated proteomics and metabolomics approach for defining oncofetal biomarkers in the colorectal cancer. Ann Surg 2012;255:720-30.
57. Nishiumi S, Kobayashi T, Ikeda A, Yoshie T, Kibi M, Izumi Y, et al. A novel serum metabolomics-based diagnostic approach for colorectal cancer. PLoS ONE [Electronic Resource] 2012;7:e40459.
58. Li F, Qin X, Chen H, Qiu L, Guo Y, Liu H, et al. Lipid profiling for early diagnosis and progression of colorectal cancer using directinfusion electrospray ionization Fourier transform ion cyclotron resonance mass spectrometry. Rapid Commun Mass Spectrom 2013;27:24-34.
59. Li S, Guo B, Song J, Deng X, Cong Y, Li P, et al. Plasma choline-containing phospholipids: potential biomarkers for colorectal cancer progression. Metabolomics 2013;9:202-12.
60. Tan B, Qiu Y, Zou X, Chen T, Xie G, Cheng Y, et al. Metabonomics identifies serum metabolite markers of colorectal cancer. J Proteome Res 2013;12:3000-9.
61. Wang C, Li P, Lian A, Sun B, Wang X, Guo L, et al. Blood volatile compounds as biomarkers for colorectal cancer. Cancer Biol Ther 2014;15:200-6.
62. Zamani Z, Arjmand M, Vahabi F, Eshaq Hosseini SM, Fazeli SM, Iravani A, et al. A metabolic study on colon cancer using (1)h nuclear magnetic resonance spectroscopy. Biochem Res Int 2014;2014:348712.
63. Zhu J, Djukovic D, Deng L, Gu H, Himmati F, Chiorean EG, et al. Colorectal cancer detection using targeted serum metabolic profiling. J Proteome Res 2014;13:4120-30.
64. Miyagi Y, Higashiyama M, Gochi A, Akaike M, Ishikawa T, Miura T, et al. Plasma free amino acid profiling of five types of cancer patients and its application for early detection. PLoS One 2011;6:e24143.
65. Ikeda A, Nishiumi S, Shinohara M, Yoshie T, Hatano N, Okuno T, et al. Serum metabolomics as a novel diagnostic approach for gastrointestinal cancer. Biomed Chromatogr 2012;26:548-58.
66. Brown SC, Kruppa G, Dasseux JL. Metabolomics applications of FT-ICR mass spectrometry. Mass Spectrom Rev 2005;24:223-31.
67. Bui T, Thompson CB. Cancer's sweet tooth. Cancer Cell 2006;9:419-20.
68. Menendez JA, Lupu R. Fatty acid synthase and the lipogenic phenotype in cancer pathogenesis. Nat Rev Cancer 2007;7:763-77.
69. Warburg O, Wind F, Negelein E. The metabolism of tumors in the body. J Gen Physiol 1927;8:519-30.
70. Bertini I, Cacciatore S, Jensen BV, Schou JV, Johansen JS, Kruhoffer M, et al. Metabolomic NMR fingerprinting to identify and predict survival of patients with metastatic colorectal cancer. Cancer Res 2012;72:356-64.
71. Farshidfar F, Weljie AM, Kopciuk K, Buie WD, MacLean A, Dixon E, et al. Serum metabolomic profile as a means to distinguish stage of colorectal cancer. Genome Med 2012;4:42.
72. Pavlou M, Diamandis EP. The search for new prostate cancer biomarkers continues. Clin Chem 2009;55:1277-9.
73. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J, et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009;457:910-4.
74. Struys EA, Heijboer AC, van Moorselaar J, Jakobs C, Blankenstein MA. Serum sarcosine is not a marker for prostate cancer. Ann Clin Biochem 2010;47:282.
75. Committee ASoP. Evans JA, Early DS, Chandraskhara V, Chathadi KV, Fanelli RD, et al. The role of endoscopy in the assessment and treatment of esophageal cancer. Gastrointest Endosc 2013;77:328-34.
76. Committee ASoP. Fisher DA, Shergill AK, Early DS, Acosta RD, Chandrasekhara V, et al. Role of endoscopy in the staging and management of colorectal cancer. Gastrointest Endosc 2013;78:8-12.
77. Kadri SR, Lao-Sirieix P, O'Donovan M, Debiram I, Das M, Blazeby JM, et al. Acceptability and accuracy of a non-endoscopic screening test for Barrett's oesophagus in primary care: cohort study. BMJ 2010;341:c4372.